The current diagnostic pathway for prostate cancer has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagnoses in many men. Multiparametric MRI (mpMRI) of the prostate has been identified as a test that could mitigate these diagnostic errors. The performance of mpMRI can vary depending on the population being studied, the execution of the MRI itself, the experience of the radiologist, whether additional biomarkers are considered and whether mpMRI-targeted biopsy is carried out alone or in addition to systematic biopsy. A number of challenges to implementation remain, such as ensuring high-quality execution and reporting of mpMRI and ensuring that this diagnostic pathway is cost-effective. Nevertheless, emerging clinical trial data support the adoption of this technology as part of the standard of care for the diagnosis of prostate cancer.

中文翻译：

---

用于前列腺癌诊断的多参数 MRI：现状和未来方向。

当前的前列腺癌诊断途径导致许多男性过度诊断和随之而来的过度治疗以及诊断不足和漏诊。前列腺的多参数 MRI (mpMRI) 已被确定为可以减少这些诊断错误的测试。mpMRI 的性能可能因所研究的人群、MRI 本身的执行、放射科医生的经验、是否考虑其他生物标志物以及 mpMRI 靶向活检是单独进行还是在系统活检之外进行而有所不同。实施方面仍然存在许多挑战，例如确保 mpMRI 的高质量执行和报告，以及确保该诊断途径具有成本效益。尽管如此，